MXPA06005643A - Compuestos novedosos. - Google Patents

Compuestos novedosos.

Info

Publication number
MXPA06005643A
MXPA06005643A MXPA06005643A MXPA06005643A MXPA06005643A MX PA06005643 A MXPA06005643 A MX PA06005643A MX PA06005643 A MXPA06005643 A MX PA06005643A MX PA06005643 A MXPA06005643 A MX PA06005643A MX PA06005643 A MXPA06005643 A MX PA06005643A
Authority
MX
Mexico
Prior art keywords
hfa
cyclodextrin
drug
formulation according
alkyl
Prior art date
Application number
MXPA06005643A
Other languages
English (en)
Spanish (es)
Inventor
Philippe Rogueda
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA06005643A publication Critical patent/MXPA06005643A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MXPA06005643A 2003-11-26 2004-11-24 Compuestos novedosos. MXPA06005643A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0303179A SE0303179D0 (sv) 2003-11-26 2003-11-26 Novel compounds
PCT/GB2004/004957 WO2005053637A2 (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hypro fluor alkane amd an acylated cyclodextrin

Publications (1)

Publication Number Publication Date
MXPA06005643A true MXPA06005643A (es) 2006-08-17

Family

ID=29729189

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06005643A MXPA06005643A (es) 2003-11-26 2004-11-24 Compuestos novedosos.

Country Status (23)

Country Link
US (1) US20070104652A1 (enExample)
EP (1) EP1708679B1 (enExample)
JP (1) JP4950666B2 (enExample)
KR (1) KR20060118509A (enExample)
CN (1) CN100592908C (enExample)
AT (1) ATE413868T1 (enExample)
AU (1) AU2004294775B2 (enExample)
BR (1) BRPI0416992A (enExample)
CA (1) CA2546441C (enExample)
CY (1) CY1108753T1 (enExample)
DE (1) DE602004017783D1 (enExample)
DK (1) DK1708679T3 (enExample)
ES (1) ES2314469T3 (enExample)
IL (1) IL175659A (enExample)
MX (1) MXPA06005643A (enExample)
NO (1) NO20062969L (enExample)
NZ (1) NZ547355A (enExample)
PL (1) PL1708679T3 (enExample)
PT (1) PT1708679E (enExample)
SE (1) SE0303179D0 (enExample)
SI (1) SI1708679T1 (enExample)
WO (1) WO2005053637A2 (enExample)
ZA (1) ZA200604330B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk IgE抗体抑制剤および食品
JPWO2023127219A1 (enExample) * 2021-12-28 2023-07-06

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US5654442A (en) * 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
TW249226B (enExample) * 1990-04-04 1995-06-11 Aderk Ueno Kk
EP0477931B1 (en) * 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln

Also Published As

Publication number Publication date
AU2004294775B2 (en) 2007-12-20
ZA200604330B (en) 2007-11-28
HK1108390A1 (zh) 2008-05-09
US20070104652A1 (en) 2007-05-10
JP2007515401A (ja) 2007-06-14
PT1708679E (pt) 2008-12-29
NO20062969L (no) 2006-08-25
CY1108753T1 (el) 2014-04-09
JP4950666B2 (ja) 2012-06-13
SE0303179D0 (sv) 2003-11-26
WO2005053637A3 (en) 2007-06-28
CN101087600A (zh) 2007-12-12
CA2546441C (en) 2011-11-22
DE602004017783D1 (de) 2008-12-24
IL175659A (en) 2010-02-17
CA2546441A1 (en) 2005-06-16
KR20060118509A (ko) 2006-11-23
ES2314469T3 (es) 2009-03-16
ATE413868T1 (de) 2008-11-15
WO2005053637A2 (en) 2005-06-16
EP1708679B1 (en) 2008-11-12
CN100592908C (zh) 2010-03-03
IL175659A0 (en) 2006-09-05
SI1708679T1 (sl) 2009-04-30
BRPI0416992A (pt) 2007-02-06
PL1708679T3 (pl) 2009-04-30
NZ547355A (en) 2009-05-31
EP1708679A2 (en) 2006-10-11
AU2004294775A1 (en) 2005-06-16
DK1708679T3 (da) 2009-02-16

Similar Documents

Publication Publication Date Title
Myrdal et al. Advances in metered dose inhaler technology: formulation development
JP6348645B2 (ja) 2つ以上の活性剤を呼吸器送達するための組成物、方法および系
JP4824267B2 (ja) 医療用エアゾール配合物
CN100337614C (zh) 医用气溶胶制剂
SK81197A3 (en) Aerosol drug formulations, method for production thereof and its use
EP0526481A1 (en) USE OF FLUORINATED SOLUBLE SURFACTANTS FOR THE PRODUCTION OF AEROSOLIC DRUGS WITH DOSAGE DELIVERY.
JPH07502275A (ja) 懸濁エアゾール製剤
US7163672B2 (en) Pharmaceutical aerosol formulation
JP6568511B2 (ja) 改善された医薬エアゾール製剤
JP5938476B2 (ja) 呼吸器疾患を治療するための定量噴霧式吸入剤を調製する方法
ES2259915B1 (es) Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion.
CA2546441C (en) Novel compounds
HK1108390B (en) Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin
Sallam Recent advances in the formulation development of inhalational dosage forms
JPH05148185A (ja) エーロゾル組成物の製造方法
HK1176550B (en) The preparation for formulation composition and manufacturing processes of metered does inhalers treated respiratory diseases
HK1176550A (en) The preparation for formulation composition and manufacturing processes of metered does inhalers treated respiratory diseases
HK1097777B (en) Medicinal aerosol formulation

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general